Allergan to cash in on eyelash stimulant effect of glaucoma drug


Following positive clinical trial results, Allergan, the makers of bimatoprost, are submitting a new drug application (NDA) to the US Food and Drug Administration (FDA), seeking a new indication for the prostaglandin analogue as an eyelash growth stimulant.

Related Videos
Josefina Botta, MD, MSc, at ASCRS 2024
Dr Nir Shoham Hazon, Director, Miramichi EyeNB Centre of Excellence, New Brunswick, Canada
J. Morgan Micheletti, MD, speaks at the 2024 ASCRS meeting
Dr William Wiley of Cleveland Eye Clinic, Northeast Ohio
© 2024 MJH Life Sciences

All rights reserved.